Company Overview
Company Type: Private Company
Company Status: Liquidating
Website: generex.com/index.html
Global Number of Employees (Latest): 15
Year Founded: 1983
Total Amount Raised (CAD mm)†: 203.98
Total Rounds of Funding**:31
Latest Post-Money Valuation ($ mm) -
Latest Pre-Money Valuation ($ mm) -
† This number reflects the estimated value of the total new money raised through private placement rounds.
** This value is an estimate of the total number of funding rounds this company has received.


Business Description
Generex Biotechnology Corporation, through its subsidiaries, engages in the administration of formulations of large molecule drugs to the oral cavity using a hand-held aerosol applicator in Canada and the United States. It offers Generex Oral-lyn, an oral insulin product. The company is also developing AE37, a synthetic peptide vaccine, which has completed Phase IIb clinical trial to stimulate a potent and specific immune response against tumors expressing the HER-2/neu oncogene in patients with breast cancer and prostate cancer. In addition, it develops, manufactures, and distributes rapid point-of-care in-vitro medical diagnostics for infectious diseases, such as human immunodeficiency virus, tuberculosis, malaria, hepatitis B, hepatitis C, syphilis, and others; and test kits and cassettes for testing infectious diseases, as well as Excellagen, a wound conforming gel. Further, the company is developing immunotherapeutic products and vaccines; and extracellular matrix hydrogel solution, a tissue engineered therapy for the treatment of Ulcerative Colitis. Additionally, it manufactures and sells foot and ankle surgical kits that include plates, screws, and tools; and distributes surgical supplies, orthopedic implants, artificial joints, and biologics, medical devices, and regenerative medicine products. It also serves as the general partner of the Management Services Organization. Generex Biotechnology Corporation was founded in 1983 and is headquartered in Miramar, Florida. On April 23, 2022, an involuntary petition for liquidation under Chapter 7 was filed against Generex Biotechnology Corporation in the U.S. Bankruptcy Court for the Southern District of Florida. On June 6, 2022, the involuntary petition was approved by the Court.

Financial Information (Currency: CAD, in mm) 
Total Revenue
0.9
Market Capitalization
0.0
EBITDA
(45.6)
EBIT
(46.9)
Cash & ST Invst.
2.3
P/Diluted EPS Before Extra
NM
Net Income
(51.0)
Total Debt
14.5
Price/Tang BV
NM
Capital Expenditure
0.0
Total Assets
62.8
Total Debt/EBITDA
NM
U.S. Number of Employees 2018
88
U.S. Number of Employees 2017
-
U.S. Last Year Employee Growth %
-
Currency in CAD in mm, LTM as of Apr-30-2021 TEV and Market Cap are calculated using a close price as of Jan-25-2023

Key Professionals
Name
Title
Moscato, Joseph 
CEO, President & Chairman of the Board
Corrao, Mark 
CFO & Treasurer
Thompson, Terry R.
Chief Operating Officer
Ro, Andrew 
Chief Investment Officer & Director
Terrell, Jason Bradley
Chief Scientific Officer & Chief Medical Officer
Crisci, Anthony S.
Chief Legal Officer & Chief Administrative Officer
Starr, Michelle 
Chief Marketing Officer
Dolisi, Anthony J.
Chief Commercial Officer
Purcell, Richard D.
Executive Vice President of Research & Drug Development

Key Board Members
Name
Title
Moscato, Joseph 
CEO, President & Chairman of the Board
Ro, Andrew 
Chief Investment Officer & Director
Anderson, James H.
Independent Director
McGee, Brian T.
Independent Director
Davis, Jonathan 
Member of Scientific Advisory Board
Eagle, Craig 
Independent Director & Member of Scientific Advisory Board
Noel, Gary J.
Member of Scientific Advisory Board
Prioletti, Mark Joseph-S.E
Independent Director
Salvo, Lawrence Anthony
Independent Director
Sanders, John 
Member of Scientific Advisory Board


Primary Industry Classification
Biotechnology


Primary Office Location
10102 USA Today Way Suite 200 | Miramar, FL | 33025 | United States
Phone: 416 364 2551   

Current and Pending Investors
Investor
Initial Investment Date
Stake Type
Current Stake Amount
Round(s)
Anson Funds Management LP
Aug-04-2020
Unknown
-
PIPE
Anson Group
Aug-04-2020
Unknown
-
PIPE
L1 Capital Pty. Limited
Aug-04-2020
Unknown
-
PIPE
Cowen Inc.
Mar-31-2008
Minority
-
PIPE
Rockmore Capital, LLC
Jun-01-2006
Unknown
-
PIPE

Prior Investors
Alexandra Global Master Fund, Ltd., Alexandra Investment Management, LLC, Ascend Capital, LLC, Ascend Partners Fund I LP, Capital Ventures International, L.P., Castle Creek Healthcare Partners LLC, Castle Creek Partners, LP, Cityplatz Ltd, Elan Corporation Limited, Elliott Associates, L.P., Elliott International Ltd, Elliott Management Corporation, Fidelity National Title Insurance Company, Gryphon Investors Inc, Gryphon Management Partners, L.P., Gryphon Master Fund LP, Gryphon Partners, L.P., Heights Capital Management, Inc., Iroquois Capital Management, LLC, Iroquois Capital Opportunity Fund, L.P., Iroquois Capital, LP, Iroquois Master Fund Ltd., Langley Capital LLC, Langley Partners, L.P., LH Financial Services Corporation, Montrose Investments Ltd., Nob Hill Capital Management, Inc., Nob Hill Capital Partners, L.P., Omicron Capital, L.P., Omicron Master Trust, Prism Partners I, L.P., Prism Partners II Offshore Fund, Prism Partners Offshore Funds, Protius Overseas Limited, RAM Trading Ltd., SMALLCAP World Fund, Inc. (MutualFund:SMCW.X), The Capital Group Companies, Inc., Velocity Capital Management, L.L.C., WEC Asset Management, LLC, Weintraub Capital Management, L.P., Willow Creek Capital Management LLC, Willow Creek Capital Partner LP, ZLP Master Technology Fund, Ltd.

Investment Arms
Generex Biotechnology Corp., Asset Management Arm


Company Notes
No Company Notes exist.


Strategy Notes
No Strategy Notes exist.


Current and Pending Subsidiaries / Investments
Company Name
Business Description
Geography
Primary Industry
LTM Total Rev.($mm)
LFQ Total Assets ($mm)
LFQ Total Debt ($mm)
Altucell, Inc. (Pending)
Altucell, Inc. develops molecular and regenerative therapy through cellular engineering for treatment of diabetes and other autoimmune and neurodegenerative diseases. The company is based in Deer Park, New York.

United States and Canada
Biotechnology
-
-
-
Assets of Pantheon Medical-Foot & Ankle
As of July 11, 2019, Assets of Pantheon Medical-Foot & Ankle was acquired by Generex Biotechnology Corporation. Assets of Pantheon Medical-Foot & Ankle comprises orthopedic surgery device manufacturing business and is located in the United States.

United States and Canada
Health Care Equipment
-
-
-
Regentys Corporation
Regentys Corporation operates as a development stage regenerative medicine company that focuses on developing treatments for patients with gastrointestinal disorders. It offers ExtraCellular Matrix Hydrogel, a non-pharmacologic and non-surgical treatment option for patients suffering from Ulcerative Colitis. Regentys Corporation was formerly known as Asana Medical, Inc. and changed its name to Regentys Corporation in November 2017. The company was founded in 2013 and is based in Miami Lakes, Florida. As of January 7, 2019, Regentys Corporation operates as a subsidiary of Generex Biotechnology Corporation.

United States and Canada
Health Care Equipment
-
-
-
Olaregen Therapeutix Inc.
Olaregen Therapeutix Inc. manufactures and develops regenerative medicine and drugs. It manufactures Excellagen, a topically applied product for dermal wounds and other indications. The company was incorporated in 2017 and is based in New York, New York. As of February 14, 2020, Olaregen Therapeutix Inc. operates as a subsidiary of Generex Biotechnology Corporation.

United States and Canada
Pharmaceuticals
-
-
-
Pro Pharmacy Health, Inc.
As of June 30, 2017, Pro Pharmacy Health, Inc. operates as a subsidiary of Generex Biotechnology Corporation.

United States and Canada
-
-
-
-
Serene Pharmacy, LLC
As of June 23, 2017, Serene Pharmacy, LLC operates as a subsidiary of Generex Biotechnology Corporation.

United States and Canada
-
-
-
-
High Desert Diagnostic Laboratory, Inc.
 As of February 21, 2017, High Desert Diagnostic Laboratory, Inc. operates as a subsidiary of Generex Biotechnology Corporation.

United States and Canada
-
-
-
-


Last 5 Transactions
Announced Date
Closed Date
Transaction Type
Role
Target
Buyer/Investors
Sellers
Size($mm)
Apr-23-2022
-
Bankruptcy
Target
Generex Biotechnology Corporation


-
Jul-15-2021
Jul-15-2021
Private Placement
Target
Generex Biotechnology Corporation


1.00
Feb-17-2021
Feb-17-2021
Private Placement
Target
Generex Biotechnology Corporation


1.43
Aug-20-2020
Sep-14-2020
Shelf Registration
Target
Generex Biotechnology Corporation

Anson Funds Management LP,Anson Group,L1 Capital Pty. Limited Seller Funds:Anson East Master Fund L.P., Anson Investments Master Fund LP, L1 Capital Global Opportunities Master Fund, Ltd.
69.12
Aug-04-2020
Aug-04-2020
Private Placement
Target
Generex Biotechnology Corporation
Anson Funds Management LP,Anson Group,L1 Capital Pty. Limited Buyer Funds:Anson East Master Fund L.P., Anson Investments Master Fund LP, L1 Capital Global Opportunities Master Fund, Ltd.

2.00
* denotes that the relationship is proprietary


Last 5 Key Developments
Date
Event Type
Headline
Jun-06-2022
Bankruptcy - Other
Involuntary Petition Approved for Generex Biotechnology Corporation
Apr-23-2022
Bankruptcy - Filing
Involuntary Petition Filed Against Generex Biotechnology Corporation
Nov-01-2021
Delayed SEC Filings
Generex Biotechnology Corporation announced delayed annual 10-K filing
Jul-23-2021
Strategic Alliances
Generex Biotechnology Corporation Enters into Quality Agreement with PPD Development, L.P
Jul-15-2021
Private Placements
Generex Biotechnology Corporation announced that it has received $1 million in funding

M&A Advisors
Eckert Seamans Cherin & Mellott, LLC, Legend Securities, Inc., Seahawk Capital Partners, Inc.


Advisors
Most Recent Auditor
Mazars S.R.O.
M&A Advisors
Eckert Seamans Cherin & Mellott, LLC, Legend Securities, Inc., Seahawk Capital Partners, Inc.
Private Placement Advisors
Carmel, Milazzo & Feil LLP, Dawson James Securities, Inc., Direct Markets Holdings Corporation, Eckert Seamans Cherin & Mellott, LLC, Ladenburg Thalmann & Co. Inc., Pali Capital, Inc., Shemano Group, Inc.
Public Offering Advisors
Eckert Seamans Cherin & Mellott, LLC, Ellenoff Grossman & Schole LLP, Mazars USA LLP, Moore Stephens Cooper Molyneux LLP, Sichenzia Ross Ference LLP, White White & Van Etten LLP


Most Recent Auditor
Mazars


Last 10 Investment Research Documents
Contributor
Analyst
Date/Time
Company
Headline
Type
Pages
Wright Investors' Service Inc.

Dec 20, 2022 03:55 PM
Generex Biotechnology Corporation
Flow of Funds Report for Generex Biotechnology Corporation - prepared by Wright Investors Service
Notes
70
GlobalData

Dec 20, 2022 03:48 AM
Generex Biotechnology Corporation
Generex Biotechnology Corp (GNBT.OTC) - Medical Equipment - Deals and Alliances Profile
Reports
59
GlobalData

Dec 20, 2022 12:27 AM
Generex Biotechnology Corporation
Generex Biotechnology Corp (GNBT.OTC) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
Reports
85
GlobalData

Dec 09, 2022 10:15 PM
Generex Biotechnology Corporation
Generex Biotechnology Corp (GNBT.OTC) - Pharmaceuticals and Healthcare Product Pipeline Summary
Reports
52
GlobalData

Sep 26, 2022 07:04 AM
Generex Biotechnology Corporation
Generex Biotechnology Corp (GNBT.OTC) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
Reports
85
GlobalData

Sep 26, 2022 06:51 AM
Generex Biotechnology Corporation
Generex Biotechnology Corp (GNBT.OTC) - Medical Equipment - Deals and Alliances Profile
Reports
58
GlobalData

Sep 15, 2022 01:05 AM
Generex Biotechnology Corporation
Generex Biotechnology Corp (GNBT.OTC) - Pharmaceuticals and Healthcare Product Pipeline Summary
Reports
52
S&P Global Compustat

Sep 01, 2022 03:05 AM
Generex Biotechnology Corporation
Generex Biotechnology Corp 2022_09_01
Reports
16
S&P Global Compustat

Aug 04, 2022 02:55 AM
Generex Biotechnology Corporation
Generex Biotechnology Corp 2022_08_04
Reports
16
S&P Global Compustat

Jul 07, 2022 02:55 AM
Generex Biotechnology Corporation
Generex Biotechnology Corp 2022_07_07
Reports
16



Top Buyers
No Top Buyers data available.

Top Sellers
Sellers
Common Stock Equivalent Held
Change
Coston, McIsaac, and Partners Inc.
0
(28,572)


S&P Global Ratings Credit Ratings
No S&P Global Ratings Credit Ratings data available. 


News Headlines
No News is currently available for the selected sources.


Company Coverage
This company is not on any Coverage List.

Products
Altsulin (Future), BaBOOM Energy Spray, cannabis Products, Crave-NX, Crave-NX 7-Day Diet Aid Spray, Fentanyl (Future), Gluco-gyn, GlucoBreak, Glucose Rapidspray, Ii-Key-SARS-CoV-2, LWH (Future), Management Services, Maxim X-Treme System, MetControl (Future), Morphine (Future), NGDx -Malaria PF/PV Cassette Test Kit, The Express II Syphilis Treponemal Assay, Trastuzumab (Future), Vaccine Peptides (Future)


Recent Major Filings

Key Filings
Filed On
Period Date
Company Name
Source
Form Type
Size
Nov-01-2021
Jul-31-2021
Generex Biotechnology Corporation
SEC
NT 10-K
25 KB
Jul-23-2021
Jul-22-2021
Generex Biotechnology Corporation
SEC
8-K (8.01, 9.01)
23 KB
Jul-21-2021
Jul-15-2021
Generex Biotechnology Corporation
SEC
8-K (1.01, 2.03, 3.02)
26 KB
Jun-21-2021
Apr-30-2021
Generex Biotechnology Corporation
SEC
10-Q
5 MB
Jun-14-2021
Apr-30-2021
Generex Biotechnology Corporation
SEC
NT 10-Q
26 KB
May-12-2021
May-10-2021
Generex Biotechnology Corporation
SEC
8-K (8.01)
24 KB
Apr-29-2021
Apr-28-2021
Generex Biotechnology Corporation
SEC
8-K (8.01)
25 KB
Apr-27-2021
Apr-22-2021
Generex Biotechnology Corporation
SEC
8-K (8.01)
28 KB
Mar-17-2021
Jan-31-2021
Generex Biotechnology Corporation
SEC
10-Q
5 MB
Feb-23-2021
Feb-17-2021
Generex Biotechnology Corporation
SEC
8-K (1.01, 2.03, 3.02)
33 KB


Insider Trades
Holder Name
Trade Date Range
Security Type
Transacted Shares
Transaction Value Range (CAD)
Transaction Type
% Change
Source
Haines, Harold Gray
Dec-04-2018 - Dec-07-2018
Common Stock
13,720
16,246
Open Market Acquisition
New
Multiple
-
Dec-07-2018
Common Stock
420
423
Open Market Acquisition
-
Form 4
-
Dec-07-2018
Common Stock
11,200
11,489
Open Market Acquisition
-
Form 4
-
Dec-04-2018
Common Stock
777
1,594
Open Market Acquisition
-
Form 4
-
Dec-04-2018
Common Stock
1,323
2,740
Open Market Acquisition
-
Form 4
Fletcher, Mark A. (Former Executive VP, General Counsel & Secretary)
Feb-16-2016
Common Stock
130,745
6,083
Derivative Exercise and Retained Stock
39.10
Form 4
Brusegard Ph.D., David A. (Former Chief Operating Officer and Secretary)
Feb-16-2016
Common Stock
49,029
2,281
Derivative Exercise and Retained Stock
42.25
Form 4
Fletcher, Mark A. (Former Executive VP, General Counsel & Secretary)
Feb-09-2016
Common Stock
437,766
20,366
Derivative Exercise and Retained Stock
(334.83)
Form 4
Brusegard Ph.D., David A. (Former Chief Operating Officer and Secretary)
Feb-09-2016
Common Stock
115,133
5,356
Derivative Exercise and Retained Stock
12,507.13
Form 4
Excluding Automatic Transactions
Key Board Members Details
Name
Title
Phone
Fax
Email
Moscato, Joseph 
CEO, President & Chairman of the Board
(646) 599-6222
-
jmoscato@nugenerex.com
Ro, Andrew 
Chief Investment Officer & Director
416 364 2551
-

Anderson, James H.
Independent Director
416 364 2551
-

McGee, Brian T.
Independent Director
416 364 2551
-

Davis, Jonathan 
Member of Scientific Advisory Board
416 364 2551
-

Eagle, Craig 
Independent Director & Member of Scientific Advisory Board
416 364 2551
-

Noel, Gary J.
Member of Scientific Advisory Board
416 364 2551
-

Prioletti, Mark Joseph-S.E
Independent Director
416 364 2551
-

Salvo, Lawrence Anthony
Independent Director
416 364 2551
-

Sanders, John 
Member of Scientific Advisory Board
416 364 2551
-

* denotes that the relationship is proprietary

Key Executives and Professionals Details
Name
Title
Phone
Fax
Email
Moscato, Joseph 
CEO, President & Chairman of the Board
(646) 599-6222
-
jmoscato@nugenerex.com
Corrao, Mark 
CFO & Treasurer
416 364 2551
-

Thompson, Terry R.
Chief Operating Officer
416 364 2551
-

Ro, Andrew 
Chief Investment Officer & Director
416 364 2551
-

Terrell, Jason Bradley
Chief Scientific Officer & Chief Medical Officer
416 364 2551
-

Crisci, Anthony S.
Chief Legal Officer & Chief Administrative Officer
416 364 2551
-

Starr, Michelle 
Chief Marketing Officer
416 364 2551
-
-
Dolisi, Anthony J.
Chief Commercial Officer
416 364 2551
-

Purcell, Richard D.
Executive Vice President of Research & Drug Development
416 364 2551
-
rpurcell@respirerx.com
* denotes that the relationship is proprietary

Historical Equity Pricing Data supplied by Interactive Data Pricing and Reference Data LLC 
S&P Credit Ratings and Research provided by 
No content (including ratings, credit-related analyses and data, valuations, model, software or other application or output therefrom) or any part thereof (Content) may be modified, reverse engineered, reproduced or distributed in any form by any means, or stored in a database or retrieval system, without the prior written permission of S&P Global Market Intelligence or its affiliates (collectively, S&P Global). The Content shall not be used for any unlawful or unauthorized purposes. S&P Global and any third-party providers, as well as their directors, officers, shareholders, employees or agents (collectively S&P Global Parties) do not guarantee the accuracy, completeness, timeliness or availability of the Content. S&P Global Parties are not responsible for any errors or omissions (negligent or otherwise), regardless of the cause, for the results obtained from the use of the Content, or for the security or maintenance of any data input by the user. The Content is provided on an "as is" basis. S&P GLOBAL PARTIES DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING, BUT NOT LIMITED TO, ANY WARRANTIES OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE OR USE, FREEDOM FROM BUGS, SOFTWARE ERRORS OR DEFECTS, THAT THE CONTENT’S FUNCTIONING WILL BE UNINTERRUPTED OR THAT THE CONTENT WILL OPERATE WITH ANY SOFTWARE OR HARDWARE CONFIGURATION. In no event shall S&P Global Parties be liable to any party for any direct, indirect, incidental, exemplary, compensatory, punitive, special or consequential damages, costs, expenses, legal fees, or losses (including, without limitation, lost income or lost profits and opportunity costs or losses caused by negligence) in connection with any use of the Content even if advised of the possibility of such damages.

Credit-related and other analyses, including ratings, and statements in the Content are statements of opinion as of the date they are expressed and not statements of fact. S&P Global Market Intelligence’s opinions, analyses and rating acknowledgment decisions (described below) are not recommendations to purchase, hold, or sell any securities or to make any investment decisions, and do not address the suitability of any security. S&P Global Market Intelligence assumes no obligation to update the Content following publication in any form or format. The Content should not be relied on and is not a substitute for the skill, judgment and experience of the user, its management, employees, advisors and/or clients when making investment and other business decisions. S&P Global Market Intelligence does not act as a fiduciary or an investment advisor except where registered as such. While S&P Global Market Intelligence has obtained information from sources it believes to be reliable, S&P Global Market Intelligence does not perform an audit and undertakes no duty of due diligence or independent verification of any information it receives.

S&P Global keeps certain activities of its divisions separate from each other in order to preserve the independence and objectivity of their respective activities. As a result, certain divisions of S&P Global may have information that is not available to other S&P Global divisions. S&P Global has established policies and procedures to maintain the confidentiality of certain non-public information received in connection with each analytical process.

S&P Global Ratings does not contribute to or participate in the creation of credit scores generated by S&P Global Market Intelligence. Lowercase nomenclature is used to differentiate S&P Global Market Intelligence PD credit model scores from the credit ratings issued by S&P Global Ratings.

S&P Global may receive compensation for its ratings and certain analyses, normally from issuers or underwriters of securities or from obligors. S&P Global reserves the right to disseminate its opinions and analyses. S&P Global's public ratings and analyses are made available on its Web sites, www.standardandpoors.com (free of charge), and www.capitaliq.com (subscription), and may be distributed through other means, including via S&P Global publications and third-party redistributors. Additional information about our ratings fees is available at www.standardandpoors.com/usratingsfees.
Regulatory News Service data provided by 
